Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
April 20, 2021

Second indication of Sarclisa for relapsed multiple myeloma approved by EC

The second indication of Sarclisa (isatuximab) for the treatment of adult patients with relapsed multiple myeloma, was approved by the European Commission (EC).

This second approval of Sarclisa is in combination with carfilzomib and dexamethasone (Kd) for adult patients who have received at least one prior therapy. Credit: Anton/Unsplash.